Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of pembrolizumab and paclitaxel in hormone receptor-positive, hypermutated metastatic breast cancer (MUTATION2)
KCT0005975Phase 2Withdrawn
- Sponsor
- Merck & Co.
- Start
- Jan 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, paclitaxel in breast cancer, sponsored by Merck & Co.. Planned start Jan 2022; status: withdrawn.
02
Drugs
pembrolizumabpaclitaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on KCT0005975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0005975.